about the" PLX cell program in critical limb ischemia that has been selected for the European Medicines Agency's Adaptive Pathways pilot project".
He and the company are very proud of the achievement.
"The announcement of PLURISTEM most dramatic in recent years" - he said
google - bizportal of today. The first T.V Interview.....with Yanai picture.
Less than 3-4 years of clinical trials.
Saving tens of millions of dollars.
A large market in Europe.